Key facts
- SeaBeLife Biotech’s last known valuation is $3.6M (May 2021).
- It has raised $8.1M; the latest was Later Stage VC ($2.4M) in Oct 2025.
- Notable investors include Bpifrance, Angels Santé, Ava Capital club, Breizh Angels, Breton Business Angels — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for SeaBeLife Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for SeaBeLife Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SeaBeLife Biotech
Operator of a biotechnology company designed to bring a new standard of care to patients suffering from serious diseases with significant unmet medical needs in the orphan, acute, and chronic disease segments. The company develops first-in-class molecules based on an innovative mechanism of action to directly and simultaneously block two synergistic regulated cell death pathways, shown to be involved and synergistic in numerous acute and chronic pathologies, enabling organizations to improve the lives of patients and save lives by avoiding complications in their services.
- Sector
- Healthcare
- HQ
- Roscoff, France
- Founded
- 2019
- Employees
- 8
- Website
- seabelife.com/
- Ownership
- Privately Held (backing)
SeaBeLife Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SeaBeLife Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SeaBeLife Biotech in its N-PORT filings yet. We sweep new filings monthly.